anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Many tools have been used to assess frailty in the perioperative setting. However, no single scale has been shown to be the most effective in predicting postoperative complications. We evaluated the relationship between several frailty scales and the occurrence of complications following different non-cardiac surgeries.
METHODS: This systematic review was registered in PROSPERO (CRD42023473401). The search strategy included PubMed, Google Scholar, and Embase, covering manuscripts published from January 2000 to July 2023. We included prospective and retrospective studies that evaluated frailty using specific scales and tracked patients postoperatively. Studies on cardiac, neurosurgical, and thoracic surgery were excluded because of the impact of underlying diseases on patients' functional status. Narrative reviews, conference abstracts, and articles lacking a comprehensive definition of frailty were excluded.
RESULTS: Of the 2204 articles identified, 145 were included in the review: 7 on non-cardiac surgery, 36 on general and digestive surgery, 19 on urology, 22 on vascular surgery, 36 on spinal surgery, and 25 on orthopedic/trauma surgery. The reviewed manuscripts confirmed that various frailty scales had been used to predict postoperative complications, mortality, and hospital stay across these surgical disciplines.
CONCLUSION: Despite differences among surgical populations, preoperative frailty assessment consistently predicts postoperative outcomes in non-cardiac surgeries.
Hepatic schistosomiasis is a prevalent form of chronic liver disease that drastically affects human health. Nevertheless, an antifibrotic drug that could suppress the development of hepatic fibrosis does not exist yet. The current study aimed to evaluate the effect of resveratrol, a natural polyphenol with multiple biological activities, on Schistosoma mansoni (S. mansoni)-induced hepatic fibrosis and delineate the underlying molecular mechanism. Swiss male albino mice were randomly assigned into infected and non-infected groups. Hepatic schistosomiasis infection was induced via exposure to S. mansoni cercariae. 6 weeks later, resveratrol was administrated either as 20 mg/kg/day or 100 mg/kg/day for 4 weeks to two infected groups. Another group received vehicle and served as infected control group. At the end of the study, portal hemodynamic, biochemical, and histopathological evaluation of liver tissues were conducted. Remarkably, resveratrol significantly reduced portal pressure, portal and mesenteric flow in a dose-dependent manner. It improved several key features of hepatic injury as evidenced biochemically by a significant reduction of bilirubin and liver enzymes, and histologically by amelioration of the granulomatous and inflammatory reactions. In line, resveratrol reduced the expression of pro-inflammatory markers; TNF-α, IL-1β and MCP-1 mRNA, together with fibrotic markers; collagen-1, TGF-β1 and α-SMA. Moreover, resveratrol restored SIRT1/NF-κB balance in hepatic tissues which is the main switch-off control for all the fibrotic and inflammatory mechanisms. Taken together, it can be inferred that resveratrol possesses a possible anti-fibrotic effect that can halt the progression of hepatic schistosomiasis via targeting SIRT1/ NF-κB signaling.
The present invention relates to a recovery capsule for treating gonorrhea, which is prepared from the components of rice bean, mung bean, ginger, etc. through the technologies of pulverization, blending, drying, disinfection and encapsulation. The recovery capsule has the effects of nourishing yin, tonifying the kidney, promoting diuresis, treating gonorrhea, strengthening immunity of an organism and regulating the functions of organs. The recovery capsule of the present invention can prevent and treat diseases, and is a pure natural and special nutritive food for promoting diuresis and treating gonorrhea. The rice bean has the functions of invigorating the spleen, promoting diuresis and detoxicating, and is used for treating edema due to deficiency of the spleen and dysuria; simultaneously, the rice bean contains abundant nutrient components, such as proteins, fat, urease and canavanine. The mung bean has the functions of clearing summerheat and promoting diuresis, contains abundant phosphorus, calcium, ferrum, carotenes, vitamin B1 and vitamin B2, and has an obvious effect of detoxification. The ginger can treat Yin deficiency and internal heat, and contains abundant amino acids and starch. Due to the cooperation of the foods, the recovery capsule has the efficacy of promoting diuresis, detoxicating toxin and treating gonorrhea.
Hemodynamic Effects

Patients with chronic angina treated with RANEXA in controlled clinical studies had minimal changes in mean heart rate (< 2 bpm) and systolic blood pressure (< 3 mm Hg). Similar results were observed in subgroups of patients with CHF NYHA Class I or II, diabetes, or reactive airway disease, and in elderly patients. 

Electrocardiographic Effects 

Dose and plasma concentration-related increases in the QTc interval [see Warnings and Precautions (5.1)], reductions in T wave amplitude, and, in some cases, notched T waves, have been observed in patients treated with RANEXA. These effects are believed to be caused by ranolazine and not by its metabolites. The relationship between the change in QTc and ranolazine plasma concentrations is linear, with a slope of about 2.6 msec/1000 ng/mL, through exposures corresponding to doses several-fold higher than the maximum recommended dose of 1000 mg twice daily. The variable blood levels attained after a given dose of ranolazine give a wide range of effects on QTc. At Tmax following repeat dosing at 1000 mg twice daily, the mean change in QTc is about 6 msec, but in the 5% of the population with the highest plasma concentrations, the prolongation of QTc is at least 15 msec. In cirrhotic subjects with mild or moderate hepatic impairment, the relationship between plasma level of ranolazine and QTc is much steeper [see Contraindications (4)]. 

Age, weight, gender, race, heart rate, congestive heart failure, diabetes, and renal impairment did not alter the slope of the QTc-concentration relationship of ranolazine. 

No proarrhythmic effects were observed on 7-day Holter recordings in 3162 acute coronary syndrome patients treated with RANEXA. There was a significantly lower incidence of arrhythmias (ventricular tachycardia, bradycardia, supraventricular tachycardia, and new atrial fibrillation) in patients treated with RANEXA (80%) versus placebo (87%), including ventricular tachycardia ≥ 3 beats (52% versus 61%). However, this difference in arrhythmias did not lead to a reduction in mortality, a reduction in arrhythmia hospitalization, or a reduction in arrhythmia symptoms.
The invention provides a method of forming dental restorations, particularly dental crowns. The method involves applying a flexible cement composition to a prepared tooth surface. The composition is polymerized so that it substantially hardens. A composite crown- forming material is dispensed into a substantially transparent plastic matrix. The matrix is placed in the mouth of the patient so that the composite material is molded over the tooth surface.  Then, the material is irradiated with curing light, through the matrix, so that it hardens to form a dental crown. The crown has good mechanical strength and is resistant to fracturing and breaking.
In three placebo-controlled, 12-week trials, the incidence of consecutive elevations (≥3 X ULN) in serum transaminases was 1.7% overall for patients treated with VYTORIN and appeared to be dose-related with an incidence of 2.6% for patients treated with VYTORIN 10/80. In controlled long-term (48-week) extensions, which included both newly-treated and previously-treated patients, the incidence of consecutive elevations (≥3 X ULN) in serum transaminases was 1.8% overall and 3.6% for patients treated with VYTORIN 10/80. These elevations in transaminases were generally asymptomatic, not associated with cholestasis, and returned to baseline after discontinuation of therapy or with continued treatment.

It is recommended that liver function tests be performed before the initiation of treatment with VYTORIN, and thereafter when clinically indicated. Patients titrated to the 10/80-mg dose should receive an additional test prior to titration, 3 months after titration to the 10/80-mg dose, and periodically thereafter (e.g., semiannually) for the first year of treatment. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return to normal. Should an increase in AST or ALT of 3 X ULN or greater persist, withdrawal of therapy with VYTORIN is recommended.

VYTORIN should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. Active liver diseases or unexplained persistent transaminase elevations are contraindications to the use of VYTORIN.
BACKGROUND: Augmentation mastopexy remains a challenging procedure. The goal is to achieve correction of breast ptosis whilst adding implant volume, and avoid complications of premature waterfall deformity, bottoming out and further revision surgery, particularly when using smooth implants. We aim to describe and evaluate a technique to reduce implant malposition in augmentation mastopexy.
METHODS: This is a technical description and retrospective review of a single surgeons' cases from 2019 to 2022 of all patients who underwent 1 stage subpectoral breast augmentation mastopexy with the inferolateral pectoralis sling.
RESULTS: Over the four year period, 284 patients (568 breasts) underwent augmentation mastopexy with the inferior pectoralis sling. Mean implant size was 360.7cc (range 180-625cc). There were no early complications and 6 (2.1%) patients had late minor complications, with five (1.8%) undergoing revision mastopexy with implant repositioning and 1 (0.4%) undergoing areola scar revision. 20 patients (7%) underwent an implant upsize procedure with the average volume increase being 218.5cc and the average time to upsize 13.6 months (range 6-36 months) CONCLUSIONS: Use of the inferolateral pectoralis muscle sling allows successful one stage augmentation mastopexy with low complication and revision rates.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Histologically HER2 negative gastric cancer patients treated with chemotherapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
NEW MATERIAL:The monoclonal antibody having specificity to human gamma-interferon and molecular weight of 26,000 and 50,000 by SDS electrophoresis in the presence of a reducing agent, belongint to IgG1 subclass, and having an adsorption capacity of >=10<7>U/mg to human gamma-interferon. USE:Reagent for the purification and determination of human gamma-interferon. PREPARATION:A female BALB/C mouse is immunized with human gamma-interferon by subcutaneous injection. After supplemental immunization, the spleen of the mouse is extracted and treated to obtain a suspension of spleen cells. The cell is fused with myeloma cell of mouse using polyethylene glycol, and the produced hybridoma is cultured in HAT medium, and is converted to monoclone by critical dilution method. The product is cultured in the abdominal cavity of a mouse, and the monoclonal antibody is separated and purified from the ascites separated from the mouse.
Neuropathic pain can occur during the prediabetic stage, even in the absence of hyperglycemia. The presence of prediabetic neuropathic pain (PDNP) poses challenges to the management of individuals with prediabetes. However, the mechanisms underlying this pain remain unclear. This study aims to investigate the underlying mechanism and identify potential therapeutic targets of PDNP. A prediabetic animal model induced by a high-energy diet exhibits both mechanical allodynia and thermal hyperalgesia. Furthermore, hyperexcitability and decreased potassium currents are observed in the dorsal root ganglion (DRG) neurons of these rats. TREK1 and TREK2 channels, which belong to the two-pore-domain K+ channel (K2P) family and play an important role in controlling cellular excitability, are downregulated in DRG neurons. Moreover, this alteration is modulated by Sortilin, a molecular partner that modulates the expression of TREK1. The overexpression of Sortilin negatively affects the expression of TREK1 and TREK2, leading to increased neuronal excitability in the DRG and enhanced peripheral pain sensitivity in rats. Moreover, the downregulation of Sortilin or activation of TREK1 and TREK2 channels by genetic or pharmacological approaches can alleviate PDNP. Therefore, targeting the Sortilin-mediated TREK1/2 pathway may provide a therapeutic approach for ameliorating PDNP.
A system and method for distribution and management of electronic vouchers (coupons) provides for embedding a Promotion Code Generator in a Carrier Application in the form of software, installing the Carrier Application on a user's computing device, using the Promotion Code Generator to generate a promotion code when the user operates the software in a predetermined manner, and validating a promotion award upon submission of the promotion code by the user to an Award Service Website for exchange and/or redemption. In the preferred system, the Carrier Application is mobile game software that is installed or downloaded to a mobile computing device. Promotion partners can initiate promotions through a Promotion Partners Website by selecting the game software, and specifying parameters for preloading it with promotions. The status of a promotion is tracked via a Promotion Bank in the promotion partner's account. The games are installed on users' mobile devices either by direct installation or by downloading from authorized distribution sites. The code generator in the game software generates promotion codes whenever the user operates the game successfully. Users can validate their awards online at the Award Service Website which updates the Promotion Bank in the partner's promotion account.
The invention discloses a Chinese medicinal preparation for treating dyspepsia. The Chinese medicinal preparation is prepared from the following bulk pharmaceuticals by weight: 20-30g of citron fruit, 20-30g of dried orange peel, 20-30g of charred hawthorn, 20-30g of Chinese mahonia, 10-20g of parslane herb, 10-20g of suberect spatholobus stem, 10-20g of honeysuckle flower, 5-15g of barbary wolfberry fruit, 5-15g of heterophylly falsestarwort root and 5-10g of American ginseng. The Chinese medicinal preparation for treating dyspepsia is mainly used for treating functional dyspepsia. During treatment, the Chinese medicinal preparation is taken orally by one dose twice every day; one course of treatment lasts for 10 days. In general, the Chinese medicinal preparation takes effects within one course of treatment, and dyspepsia can be cured after two courses of treatment. In order to consolidate the curative effect, the Chinese medicinal preparation can be taken continually for one or more courses of treatment. The Chinese medicinal preparation for treating dyspepsia is remarkable in treatment effect and free from side effects, and relapse is prevented after curing. Because raw materials used are Chinese herbal medicinal materials, the Chinese medicinal preparation is mild, non-irritant and easy to be accepted by patients, and can be popularized and applied.
The invention discloses a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-12 parts of Peristrophe roxburghiana, 10-12 parts of fructus aurantii, 9-11 parts of Radix paeoniae rubra, 10-12 parts of Ophiorrhiza sp., 6-8 parts of Ludisis discolor (Ker-Gawl.) A. Rich., 5-7 parts of Hemipilia flabellata Bur.et Franch. and 5-7 parts of Semen brassicae. According to the principle of symptomatic treatment in acute condition, the invention mainly focuses on eliminating phlegm by cooling, promoting blood circulation, removing blood stasis, eliminating phlegm and inducing resuscitation, nourishing yin and moistening lung, etc. in the acute exacerbation period, a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease is developed. The traditional Chinese medicine composition can effectively treat chronic obstructive pulmonary disease, the effective rate can reach 95%.
Articles having a complex geometric configuration have hydrophilicity imparted to at least a portion of surfaces of the articles while substantially retaining the complex geometric configuration. The hydrophilicity is imparted by an extremely thin, self-interlocking shell of tactic, hydrophilic poly(vinyl alcohol) enveloping the surfaces. A tactic poly(vinyl alcohol) precursor applied to surfaces of the supporting structure is reacted in situ on the surfaces with a hydrolysis reagent to prepare the tactic, hydrophilic poly(vinyl alcohol) shell. The article having the hydrophilic shell is highly resistant to solvent washout. Hydrophilicity and hydrophobicity can be reversibly provided on regio-specific surfaces of the article. Articles in the form of membranes useful as filters are also described.
There is detailed a variety of acidic and basic proteases produced by Dichelobacter nodosus and antibodies thereto. These proteases comprise epitopes which can be used to distinguish virulent and/or intermediate strains of D. nodosus from benign strains. The proteases can be produced by recombinant means. There is also disclosed:     1. A DNA molecule which comprises the signal peptide derived from a gene which encodes either Bacillus subtilis neutral or alkaline protease or D. nodosus serine protease. 2. A hybrid protease molecule wherein the protease portion is derived from D. nodosus or Xanthomonas campestris. 3. A peptide having an isoelectric point of 9.0-9.5 in microcystalline form.   4. The use of subtilisin-like proteases in detergents. 5. The use of D. nodosus proteases to catalyse the synthesis of proteins or peptides.
The present invention discloses a Chinese preparation for treating enteritis ulcer colitis and preparation method thereof. The present Chinese preparation was preparaed by following weight proportion of raw materials: resinous excretion from the fruits of Daemonorops draco Bl.and related spp. 1-10% , radix of Paeonia lactiflora Pall. or Paeonia veitchii Lynch or Paeonia obovata Maxim. 15-40%, Baphicacanthus cusia(Nees)Bremek. or Indigofera tinctoria L. or Isatis tinctoria L. or I. indigotica Fort. or Polygonum tinctorium Ait. 1-20%, Halloysite 1-10%, Acacia catechu(L.f.)Willd. or Uncaria gambier Roxb. 15­40%, Alunite 1-10%, rhizoma of Bletilla striata(Thunb.)Reichb. f. 5-30%, Smithsonite 1-10%. The preparation method according to the present invention: extracting radix of Paeonia lactiflora Pall. or Paeonia veitchii Lynch or Paeonia obovata Maxim. Acacia catechu(L.f.)Willd. or Uncaria gambier Roxb. , Alunite with water; mixing resinous excretion from the fruits of Daemonorops draco Bl. and related spp. with Baphicacanthus cusia(Nees)Bremek. or Indigofera tinctoria L. or Isatis tinctoria L. or I. indigotica Fort. or Polygonum tinctorium Ait. uniformly , adding polyethylene glycol solution;mesh screening rhizoma of Bletilla striata(Thunb.)Reichb. f., and mixing with above mentioned aqueous extract and polyethylene glycol solution of resinous excretion from the fruits of Daemonorops draco Bl. and related spp, Baphicacanthus cusia(Nees)Bremek. or Indigofera tinctoria L. or Isatis tinctoria L. or I. indigotica Fort. or Polygonum tinctorium Ait., adding Halloysite, Smithsonite, grinding together, adding water, forming enema. The enema according to the present invention have good short-term, long-term curative effect of treating enteritis ulcer colitis.
BACKGROUND: Anemia can lead to secondary brain damage by reducing arterial oxygen content and brain oxygen supply. Patients with acute brain injury have impaired self-regulation. Brain hypoxia may also occur even in mild anemia. Red blood cell (RBC) transfusion is associated with increased postoperative complications, poor neurological recovery, and mortality in critically ill neurologic patients. Balancing the risks of anemia and red blood cell transfusion-associated adverse effects is challenging in neurocritical settings.
METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE (PubMed) from inception to January 31, 2024. We included all randomized controlled trials (RCTs) assessing liberal versus restrictive RBC transfusion strategies in neurocritical patients. We included all relevant studies published in English. The primary outcome was mortality at intensive care unit (ICU), discharge, and six months.
RESULTS: Of 5195 records retrieved, 84 full-text articles were reviewed, and five eligible studies were included. There was no significant difference between the restrictive and liberal transfusion groups in ICU mortality (RR: 2.53, 95% CI: 0.53 to 12.13), in-hospital mortality (RR: 2.34, 95% CI: 0.50 to 11.00), mortality at six months (RR: 1.42, 95% CI: 0.42 to 4.78) and long-term mortality (RR: 1.22, 95% CI: 0.64 to 2.33). The occurrence of neurological adverse events and most major non-neurological complications was similar in the two groups. The incidence of deep venous thrombosis was lower in the restrictive strategy group (RR: 0.41, 95% CI: 0.18 to 0.91).
CONCLUSIONS: Due to the small sample size of current studies, the evidence is insufficiently robust to confirm definitive conclusions for neurocritical patients. Therefore, further investigation is encouraged to define appropriate RBC transfusion thresholds in the neurocritical setting.
Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.